Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients

Recent studies of chronic lymphocytic leukemia (CLL) show that malignant B cells proliferate at a rate similar to normal B lymphocytes. This is in apparent contradiction to the very low proliferation rate found in blood specimens from CLL patients. To address this problem, we studied the expression of Ki-67, CD38, CD25, and Zap-70 in different compartments of CLL patients. Using triple-color flow cytometry, we examined the expression of CD38, CD25, Zap-70, and Ki-67 antigens in the peripheral blood, bone marrow, spleen, and lymph nodes biopsies of patients with CLL, splenic marginal zone lymphoma (SMZL), and nonmalignant diseases. In parallel probes of lymph node/spleen biopsies and blood taken from one and the same patient, Ki-67 expression was 17 times higher. Among the whole cohort, we also found significantly higher Ki-67 expression in biopsies from lymph nodes and spleen (4.95% π 0.55%), compared with bone marrow (1.88% π 0.32%) and peripheral blood (0.45% π 0.03%, P � 0.01). In CLL patients, there are statistically significant correlations between the expression of CD38 and Ki-67 in bone marrow (P � 0.01), Zap-70 and Ki-67 in blood (P � 0.01), and Zap-70 and CD38 in blood (P � 0.01). Patients with SMZL also showed a significant correlation between Ki-67 and CD38 expression (P � 0.01) and between Ki-67 and Zap-70 expression (P � 0.01). We show for the first time that proliferation of B lymphocytes in CLL patients is associated primarily with lymph nodes/spleen. Malignant cells in the blood represent only a subpopulation of nonproliferating and less-activated B cells in this disease.

[1]  R. Bataille,et al.  CD38 expression and secondary 17p deletion are important 
prognostic factors in chronic lymphocytic leukaemia , 2002, British journal of haematology.

[2]  N. Chiorazzi,et al.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. , 2007, Blood.

[3]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[4]  G. Morgan,et al.  Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL , 2008, Leukemia & lymphoma.

[5]  S. Deaglio,et al.  In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. , 2006, Blood.

[6]  I. Chanarin,et al.  Studies in chronic lymphocytic leukaemia. The kinetics of 51Cr-labelled lymphocytes. , 2009, Scandinavian journal of haematology.

[7]  J. Dürig,et al.  Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. , 2009, Leukemia research.

[8]  R. Kusec,et al.  CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. , 2004, Blood.

[9]  A. Wiestner.  Flow cytometry for ZAP‐70: New colors for chronic lymphocytic leukemia , 2006, Cytometry. Part B, Clinical cytometry.

[10]  A. Dietz,et al.  Bi‐directional activation between mesenchymal stem cells and CLL B‐cells: implication for CLL disease progression , 2009, British journal of haematology.

[11]  Polák Jaroslav,et al.  Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia. , 2005, Leukemia & lymphoma.

[12]  F. Caligaris‐cappio.  Role of the microenvironment in chronic lymphocytic leukaemia , 2003, British journal of haematology.

[13]  P. Conte,et al.  A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  F. Ajchenbaum‐Cymbalista,et al.  Overexpression of cyclin D2 in chronic B-cell malignancies. , 1995, Blood.

[15]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[16]  D. Catovsky,et al.  Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. , 2005, Cancer.

[17]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[18]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[19]  P. Anderson,et al.  Association of a 70-kDa tyrosine phosphoprotein with the CD16: zeta: gamma complex expressed in human natural killer cells. , 1993, European journal of immunology.

[20]  G. Guida,et al.  The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. , 2003, Blood.

[21]  L. Trentin,et al.  B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. , 1997, Cancer research.

[22]  F. Bertucci,et al.  Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer , 2009, Breast Cancer Research.

[23]  A. Jack,et al.  B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle , 2007, British journal of haematology.

[24]  S. Stilgenbauer,et al.  Genetics of chronic lymphocytic leukemia. , 2011, Clinics in laboratory medicine.

[25]  F. Roviello,et al.  Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  J. Dürig,et al.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.

[27]  S. Eustace,et al.  Bone marrow. , 2010, Magnetic resonance imaging clinics of North America.

[28]  K. Kuliczkowski,et al.  High intracellular content of cyclin‐dependent kinase inhibitor p27Kip1 in early‐ and intermediate stage B‐cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease , 2009, European journal of haematology.

[29]  U. Dianzani,et al.  CD38 expression and functional activities are up‐regulated by IFN‐γ on human monocytes and monocytic cell lines , 2001, Journal of leukocyte biology.

[30]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[31]  S. Malek,et al.  Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[32]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[33]  E. Kimby,et al.  Cell surface expression of CD25, CD54, and CD95 on B‐ and T‐cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course , 2002, European journal of haematology.

[34]  L Montebugnoli,et al.  Prognostic value of Ki67 from clinically and histologically 'normal' distant mucosa in patients surgically treated for oral squamous cell carcinoma: a prospective study. , 2009, International journal of oral and maxillofacial surgery.

[35]  S. Deaglio,et al.  CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. , 2007, Blood.

[36]  S. Zupo,et al.  Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression. , 2003, Haematologica.

[37]  S. Deaglio,et al.  CD38/CD31 Interactions Activate Genetic Pathways Leading to Proliferation and Migration in Chronic Lymphocytic Leukemia Cells , 2010, Molecular medicine.

[38]  P. Anderson,et al.  Association of a 70‐kDa tyrosine phosphoprotein with the CD16:ζ:γ complex expressed in human natural killer cells , 1993 .

[39]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[40]  T. Möröy,et al.  ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.

[41]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[42]  D. Catovsky,et al.  ζ‐Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia , 2005 .

[43]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[44]  J. Salisbury,et al.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.

[45]  C. Fegan,et al.  Highly purified CD38+ sub‐populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38− sub‐populations derived from the same chronic lymphocytic leukaemia patient , 2008, British journal of haematology.

[46]  N. Probst-Hensch,et al.  AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations , 2010, Modern Pathology.

[47]  K. Kuliczkowski,et al.  Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Haematologica.

[48]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[49]  Polák Jaroslav,et al.  Expression of cyclins D1, D2 and D3 and Ki-67 in human leukemia , 2005 .

[50]  J. Roliński,et al.  Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. , 2008, Leukemia research.

[51]  I. Astsaturov,et al.  The relevance of cytological studies and Ki-67 reactivity to the clinical course of chronic lymphocytic leukemia. , 1997, Leukemia & lymphoma.

[52]  K. Lennert,et al.  Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67 , 1984, Hematological oncology.

[53]  H. Nilsson‐Ehle,et al.  Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma , 2008, Leukemia & lymphoma.